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Considerable risk for cardiovascular disease (CVD) persists in individuals treated with LDL (low-density lipoprotein) 
cholesterol–lowering statin and PCSK9 inhibitor therapies.1 
Experimental models and human genetics have indicated that 
TRLs (triglyceride-rich lipoproteins) play a causal role in the 
pathogenesis of CVD.2 Post hoc analyses of statin trials have 
further shown that reductions of TRL are associated with lower 
cardiovascular event risk independently of the LDL cholesterol 
reduction achieved from statins.3,4 These observations have ac-
celerated the development of novel TRL-lowering therapeutics 
for CVD prevention, with drug targets informed by recent dis-
coveries from genetic studies.5 These include identification of 
loss-of-function (LOF) mutations in the ANGPTL3 (angiopoi-
etin-like protein 3) causing familial combined hypolipidemia 
(FHBL2; OMIM No. 605019).6,7 This Mendelian condition is 
characterized by simultaneous presentation of low circulating 
concentrations of triglycerides, LDL cholesterol, and HDL 
(high-density lipoprotein) cholesterol levels, as well as poten-
tial beneficial effects on glucose metabolism.7
ANGPTL3 is a protein secreted by the liver, and its defi-
ciency was first identified in a hypolipidemic mouse strain.8 
The ANGPTL3 protein is as a potent inhibitor of lipopro-
tein lipase—a primary factor that clears TRL from the cir-
culation.9 Reduced ANGPTL3 also reduces hepatic apo 
(apolipoprotein) B secretion and increased hepatic LDL 
uptake, leading to reduced plasma LDL cholesterol lev-
els.10 ANGPTL3 further acts to inhibit endothelial lipase, 
which may contribute to the low HDL cholesterol levels 
in ANGPTL3 LOF carriers.11 The first human ANGPTL3 
LOF mutations described were nonsense mutations S17X 
and E129X in the first exon of the gene.6 Since the initial 
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Objective—Loss-of-function (LOF) variants in the ANGPTL3 (angiopoietin-like protein 3) have been associated with low 
levels of plasma lipoproteins and decreased coronary artery disease risk. We aimed to determine detailed metabolic 
effects of genetically induced ANGPTL3 deficiency in fasting and postprandial state.
Approach and Results—We studied individuals carrying S17X LOF mutation in ANGPTL3 (6 homozygous and 32 
heterozygous carriers) and 38 noncarriers. Nuclear magnetic resonance metabolomics was used to quantify 225 
circulating metabolic measures. We compared metabolic differences between LOF carriers and noncarriers in fasting 
state and after a high-fat meal. In fasting, ANGPTL3 deficiency was characterized by similar extent of reductions in LDL 
(low-density lipoprotein) cholesterol (0.74 SD units lower concentration per LOF allele [95% CI, 0.42–1.06]) as observed 
for many TRL (triglyceride-rich lipoprotein) measures, including VLDL (very-low-density lipoprotein) cholesterol (0.75 
[95% CI, 0.45–1.05]). Within most lipoprotein subclasses, absolute levels of cholesterol were decreased more than 
triglycerides, resulting in the relative proportion of cholesterol being reduced within TRLs and their remnants. Further, 
β-hydroxybutyrate was elevated (0.55 [95% CI, 0.21–0.89]). Homozygous ANGPTL3 LOF carriers showed essentially 
no postprandial increase in TRLs and fatty acids, without evidence for adverse compensatory metabolic effects.
Conclusions—In addition to overall triglyceride- and LDL cholesterol–lowering effects, ANGPTL3 deficiency results in 
reduction of cholesterol proportion within TRLs and their remnants. Further, ANGPTL3 LOF carriers had elevated ketone 
body production, suggesting enhanced hepatic fatty acid β-oxidation. The detailed metabolic profile in human knockouts 
of ANGPTL3 reinforces inactivation of ANGPTL3 as a promising therapeutic target for decreasing cardiovascular risk.
Visual Overview—An online visual overview is available for this article.  (Arterioscler Thromb Vasc Biol. 2019;39:665-
674. DOI: 10.1161/ATVBAHA.118.312021.)
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publications on these mutations, several other ANGPTL3 
LOF mutations have been characterized.12–14
Individuals with complete ANGPTL3 deficiency have been 
reported to lack significant coronary atherosclerotic plaques.15 
Exome sequencing of large epidemiological cohorts has fur-
ther shown that heterozygous carriers of ANGPTL3 LOF 
variants have a 35% to 40% reduced risk of coronary artery 
disease compared with the general population.15,16 Moreover, 
no increased prevalence in fatty liver disease, or other appar-
ent adverse health effects, has been identified for ANGPTL3 
LOF carriers, including homozygote carriers with complete 
ANGPTL3 deficiency.7,17 Thus, ANGPTL3 is a promising ther-
apeutic target for lowering CVD risk, and clinical trials of mon-
oclonal antibodies or antisense oligonucleotides for ANGPTL3 
inhibition have recently shown to lead to substantial lowering 
of circulating triglycerides and LDL cholesterol levels.16,18
Despite the promising results from phase 1 trials targeting 
ANGPTL3,16,18 a number of important questions of the molec-
ular effects of ANGPTL3 inhibition remain. First, it is unclear 
which specific lipid components of TRL are mostly affected 
by ANGPTL3 deficiency, and thus the underlying mechanism 
of reduced CVD risk is incompletely understood. Second, the 
effects of ANGPTL3 deficiency on many emerging biomarkers 
for cardiometabolic risk have not been addressed.9 We have pre-
viously shown that nuclear magnetic resonance (NMR) metab-
olomics is a powerful method to characterize the fine-grained 
effects of PCSK9 and HMGCR genetic variants on a lipid me-
tabolism and other metabolic pathways, with a close match to 
the changes observed in statin trials.19,20 Here, we use NMR me-
tabolomics to characterize the systemic effects of ANGPTL3 
deficiency on detailed measures of lipoprotein composition, 
fatty acids, and circulating metabolites. Because most people 
are in a nonfasting state for the majority of the day, studying 
the effects on postprandial metabolism may further contribute 
to explain the cardioprotective mechanism of ANGPTL3 de-
ficiency. We have previously reported highly reduced post-
prandial response in triglycerides among ANGPTL3 LOF 
homozygotes.21 Here, we further examined the detailed met-
abolic effects of ANGPTL3 deficiency after a high-fat meal.
Materials and Methods
The data that support the findings of this study are available from 
M.A. (marcello.arca@uniroma1.it) on reasonable request.
Study Cohort of ANGPTL3 LOF Carriers
An overview of the study design in shown in the Graphic Abstract. 
The study population and the design of the oral fat tolerance chal-
lenge have been described in detail elsewhere.21 Briefly, 6 homozy-
gous and 32 heterozygous carriers of ANGPTL3 S17X LOF mutation 
(henceforth ANGPTL3 LOF) and 38 noncarriers were considered in 
the present study. Clinical examinations and blood sample drawings 
were performed after an overnight fast, after which participants un-
derwent an oral fat tolerance test. The test meal (muffin prepared with 
olive oil, eggs, ricotta cheese, nuts, cocoa, wheat flour, and skimmed 
milk) consisted of 73 g fat, 52 g carbohydrate, 22 g protein, and 145 
mg cholesterol. Blood samples were drawn before the test meal and at 
2, 4, and 6 hours after the meal. The Ethical Committee of Sapienza 
University of Rome approved the study protocol, and all study par-
ticipants provided their informed consent.
Lipid and Metabolite Quantification
Frozen EDTA plasma samples from fasting state and those collected 
during the oral fat tolerance test were used for metabolomic analyses. 
Metabolic biomarkers were quantified using proton NMR metab-
olomics (Nightingale Health, Ltd, Helsinki, Finland). This method 
provides simultaneous quantification of routine lipids, lipoprotein 
subclass profiling with lipid concentrations within 14 subclasses, 
fatty acid composition, and various low-molecular metabolites, in-
cluding amino acids, ketone bodies, and gluconeogenesis-related 
metabolites in molar concentration units. To provide indication of 
which peaks give origin to the quantified metabolite data, represen-
tative NMR spectra of study participants at fasting and postprandial 
state are shown in Figure I in the online-only Data Supplement. More 
detailed metabolite assignment across complete spectral regions used 
has been published previously.19 Details of the experimentation and 
applications of the NMR metabolomics platform have been described 
previously.19,20,22,23
To compare measurements obtained by the Nightingale NMR 
assay and clinical chemistry, we calculated Pearson pairwise correla-
tions between some biomarkers that were obtained with both meth-
ods in our dataset; LDL and HDL cholesterol, apoA1, and apoB. The 
correlations were high for all measures in all timepoints (0.93–0.95 
for LDL cholesterol, 0.90–0.95 for HDL cholesterol, 0.79–0.84 for 
apoA1, and 0.80–0.81 for apoB). Holmes et al24 have previously re-
ported slightly lower estimates of correlation for LDL and HDL cho-
lesterol (0.86 and 0.88, respectively) but higher estimates for apoA1 
and apoB (0.87 and 0.90, respectively) based on nonfasting samples 
in a large biobank study.
Statistical Analysis
We first evaluated associations between ANGPTL3 LOF carrier status 
and fasting metabolite measures. Before analyses, the concentrations 
of all metabolic markers were log-transformed and scaled to SD units 
to enable comparison of results for measures with different units and 
across wide ranges of concentrations. As the primary analysis, we 
examined an additive model for association between metabolites and 
the 3 genotype classes (ANGPTL3 LOF homozygotes, heterozygotes, 
and noncarriers). For each metabolic measure, the concentration dif-
ference (in log-transformed and subsequently SD-scaled units) per 
ANGPTL3 LOF allele was calculated using linear regression adjusted 
for age and sex. As a secondary analysis, we studied the associations 
of complete ANGPTL3 knockouts and fasting metabolites using a re-
cessive model (homozygous carriers versus heterozygotes and noncar-
riers combined). Because of the correlated nature of metabolomics 
measures, we used false discovery rate correction and defined false 
discovery rate–corrected P <0.05 as statistically significant association.
To evaluate postprandial responses in metabolites, we calculated 
means and SEs by ANGPTL3 LOF carrier status at each timepoint. 
Postprandial dynamics in the 3 genotype classes were compared using 
net incremental area under the curve (iAUC) statistics (area under the 
curve that differs from the fasting value) with the trapezoidal rule.25 
The differences in iAUCs between the 3 genotype classes were tested 
with t tests.
Nonstandard Abbreviations and Acronyms
ANGPTL3 angiopoietin-like protein 3
Apo apolipoprotein
CVD cardiovascular disease
GlycA glycoprotein acetyl
HDL high-density lipoprotein
iAUC incremental area under the curve
IDL intermediate-density lipoprotein
LDL low-density lipoprotein
LOF loss-of-function
NMR nuclear magnetic resonance
TRL triglyceride-rich lipoprotein
VLDL very-low-density lipoprotein
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Results
Study Participants
The clinical characteristics of the study participants are sum-
marized in the Table. ANGPTL3 LOF carriers and noncarriers 
were comparable for age and sex. Heterozygous ANGPTL3 
LOF carriers had higher body mass index and waist circum-
ference than noncarriers; however, these metrics did not differ 
between homozygous and noncarrier subjects. Plasma levels 
of ANGPTL3 protein were undetectable in homozygotes, 
whereas heterozygotes had 51% lower concentration com-
pared with that of noncarriers. Previous report has shown that 
the 3 genotype classes were comparable for dietary intake, 
physical activity, smoking prevalence, and use of anti-inflam-
matory medications.21 However, we note that in the current 
study, the plasma of 1 homozygous individual ran out and 1 
additional heterozygous individual was tested for the oral fat 
load after the conclusion of the previous study.21 Descriptive 
statistics for all metabolic biomarkers tested are reported in 
Table I in the online-only Data Supplement.
Effects of ANGPTL3 LOF on Lipids and  
Metabolites at Fasting
Compared with noncarriers, carriers of ANGPTL3 LOF muta-
tions had substantially reduced levels in almost all lipid meas-
ures assayed by NMR metabolomics. These include lower 
concentrations of routine lipid measures, as well as the cho-
lesterol and triglyceride levels in major subfractions, and 
reduced concentrations of apoB and apoA1 (Figure 1; Table II 
in the online-only Data Supplement). Scaled to the same var-
iation in each lipid measure (ie, in units of SD), we observed 
comparable extent of lowering effects on LDL cholesterol 
levels (−0.74 SD units of concentration per allele [95% CI, 
−1.06 to −0.42]) as observed for VLDL (very-low-density li-
poprotein) cholesterol levels (−0.75; 95% CI, −1.05 to −0.45) 
and other measures of TRL. The lowering effect size on total 
plasma triglycerides was −0.62 (95% CI, −0.93 to −0.32). In 
absolute concentrations, these lowering effects correspond to 
0.28 mmol/L lower for LDL cholesterol, 0.13 mmol/L lower 
for VLDL cholesterol, and 0.20 mmol/L for total triglycer-
ides. Also, HDL cholesterol and other lipid measures in HDL 
particles were lowered to a similar extent when scaled to SD 
concentrations of same variation. The effects of ANGPTL3 
LOF on all tested metabolites are shown in Figures II and III 
in the online-only Data Supplement.
Zooming in on the more specific effects of ANGPTL3 
LOF on lipoprotein subclass measures, we observed sub-
stantial reduction of cholesterol concentration within all li-
poprotein subclasses (Figure 2A). The lowering effects were 
somewhat stronger for IDL (intermediate-density lipoprotein) 
in comparison with other apoB-100–containing particles. For 
HDL subclasses, cholesterol levels were most prominently 
lowered in medium-sized HDL particles. Scaled to the same 
variation, the extent of cholesterol lowering in all 10 apoB-
containing subclasses was broadly similar to that observed 
for the routine lipid measures. Analogously, the triglyceride 
concentration in all lipoprotein subclasses (except for small 
HDL) was reduced; however, the triglyceride lowering was 
to a somewhat smaller extent for IDL and other similarly 
sized lipoprotein particles than that observed for choles-
terol. Thus, even though the absolute triglyceride levels in 
lipoprotein particles were reduced, the relative proportion of 
triglycerides in TRL particles was actually increased because 
of ANGPTL3 deficiency. Concordantly, the cholesterol pro-
portion of medium-sized and small VLDL and IDL particles 
decreased (Figure 2A, bottom). The proportional measures 
of lipid content in the lipoprotein subclasses are further il-
lustrated in Figure 2B, which depicts the overall lipid com-
position for selected lipoprotein subclasses in ANGPTL3 
LOF carriers and noncarriers. For example, the proportion 
of cholesterol in small VLDL was 36% in noncarriers, 34% 
in ANGPTL3 LOF heterozygotes, and 26% in homozygotes. 
The cholesterol proportion was also reduced in large LDL 
(67%, 66%, and 62%, respectively), whereas in large HDL, 
ANGPTL3 LOF homozygotes had the highest proportion of 
cholesterol (55% versus 47% and 46% in ANGPTL3 LOF 
Table 1. Characteristics of Study Participants
Noncarriers
ANGPTL3 
Heterozygous 
Carriers
ANGPTL3 
Homozygous 
Carriers
n 38 32 6
Age, y 47.0 (12.6) 50.8 (14.5) 53.5 (24.5)
Sex, females 21 (55.3) 15 (46.9) 4 (66.7)
Body mass index, kg/m2 26.3 (4.2) 28.8 (4.4)* 27.8 (5.0)
Waist circumference, cm 92.5 (10.5) 100.7 (11.8)* 97.6 (15.0)
Statin use 1 (2.6) 2 (6.3) 0
Fasting ANGPTL3 protein 
concentration, ng/mL
208.7 (80.3) 108.3 (60.1) 0
Data are presented as mean (SD) or number of individuals (%). ANGPTL3 
indicates angiopoietin-like protein 3.
*P <0.05 when compared with noncarriers.
Figure 1. Effects of ANGPTL3 (angiopoietin-like protein 3) loss-of-func-
tion (LOF) variant on fasting lipoprotein lipids and Apo (apolipoproteins). 
Effect estimates are shown as difference in SD-scaled concentration 
units per ANGPTL3 S17X allele (additive model). Error bars indicate 95% 
CIs. Filled and open circles denote false discovery rate–corrected P 
value for association below and above 0.05, respectively. HDL indicates 
high-density lipoprotein; LDL, low-density lipoprotein; and VLDL, very-
low-density lipoprotein.
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heterozygotes and noncarriers, respectively). These values 
also demonstrate larger differences in lipoprotein meas-
ures between heterozygotes and homozygotes than between 
noncarriers and heterozygotes, suggesting more prominent 
effects of complete knockout of ANGPTL3 for these lipopro-
tein subclasses compared with the effects expected from a 
linear dose-response relation.
The substantial lowering effects of ANGPTL3 defi-
ciency on lipoprotein lipids may influence both absolute 
concentrations of circulating fatty acid and their relative 
proportions. We found that ANGPTL3 LOF carriers dis-
played a significant reduction of total fatty acids, including 
saturated, monounsaturated, and polyunsaturated omega-3 
and omega-6 fatty acids (Figure 3). Assessment of the 
proportions of fatty acid classes (ie, their ratios relative to 
total fatty acids) indicated an elevation of the proportion of 
saturated fatty acids and a reduction in the proportion of 
omega-3 fatty acids.
To assess potential nonlipid effects of ANGPTL3 defi-
ciency, we examined the changes in circulating amino acids, 
glycolysis and gluconeogenesis substrates and products, ke-
tone bodies, and other metabolites quantified simultaneously 
alongside lipid measures by the NMR metabolomics platform. 
Several of these nonlipid biomarkers also showed significant 
association with ANGPTL3 LOF carrier status (Figure 3). The 
ketone body β-hydroxybutyrate—a biomarker of hepatic fatty 
acid β-oxidation—was markedly elevated in ANGPTL3 LOF 
carriers (0.55 SD per allele; 95% CI, 0.21–0.89). Further, the 
A
Figure 2. Effects of ANGPTL3 (angiopoietin-like protein 3) loss-of-function (LOF) variant on fasting cholesterol and triglycerides concentrations in lipoprotein 
subclasses and their composition. A, Effect estimates are shown as difference in SD-scaled concentration units per ANGPTL3 S17X allele (additive model). Error 
bars indicate 95% CIs. Filled and open circles denote false discovery rate–corrected P value for association below and above 0.05, respectively. (Continued ) 
D
ow
nloaded from
 http://ahajournals.org by on October 24, 2019
Tikkanen et al  Metabolomic Signature of ANGPTL3 Deficiency  669
energy metabolism intermediate acetate was reduced (−0.56 
SD per allele; 95% CI, −0.90 to −0.22) and citrate levels 
displayed a similar tendency. Branched-chained and aro-
matic amino acids, which are biomarkers for increased type 
2 diabetes mellitus and CVD risk,23,26 did not differ between 
ANGPTL LOF carriers and noncarriers. Further, we observed 
no differences in creatinine—an indicator of kidney func-
tion—or in GlycA (glycoprotein acetyl) level—a marker of 
chronic inflammation.
In analyses employing a recessive model, there was 
evidence for individuals with complete ANGPTL3 defi-
ciency having more than twice the lipid-lowering effects of 
heterozygote ANGPTL3 LOF carriers. For example, homo-
zygous ANGPTL3 LOF carriers had on the average −1.97 
(95% CI, −2.69 to −1.25) SD units lower LDL cholesterol 
and −1.86 (95% CI, −2.56 to −1.16) lower VLDL choles-
terol, when compared with heterozygous ANGPTL3 LOF 
carriers and noncarriers. Many other lipids and lipoprotein 
measures also had substantially larger effect sizes for ho-
mozygous ANGPTL3 LOF carriers in a recessive model 
(Figures IV and V in the online-only Data Supplement; 
Table III in the online-only Data Supplement). Of nonlipid 
markers, creatinine and acetate were significantly lower in 
ANGPTL3 homozygotes.
B
ANGPTL3
Figure 2 Continued. B, Average lipid content of selected lipoprotein subclasses in ANGPTL3 LOF carriers and noncarriers are depicted to further illustrate 
the effects on lipoprotein composition. HDL indicates high-density lipoprotein; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; and 
VLDL, very-low-density lipoprotein.
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Effects of ANGPTL3 LOF on Metabolic 
Response to a Fat Challenge
To examine the effects of ANGPTL3 deficiency on postpran-
dial metabolism, we further assessed the lipoprotein and me-
tabolite trajectories after an oral fat challenge. Postprandial 
responses in selected metabolic measures for ANGPTL3 LOF 
carriers and noncarriers are shown in Figure 4. ANGPTL3 
LOF homozygotes had drastically lower concentration of cho-
lesterol in VLDL, LDL, and IDL particles in all timepoints in 
comparison with ANGPTL3 LOF heterozygotes and noncar-
riers. There was essentially no change in VLDL cholesterol 
after the fat challenge among ANGPTL3 LOF homozygotes, 
whereas ANGPTL3 LOF heterozygotes and noncarriers 
showed substantially increased levels (PiAUC=0.07 for differ-
ence in iAUC). This effect on VLDL cholesterol seemed to 
be driven particularly by differences for large and medium-
sized VLDL particles in response to the high-fat meal. For 
instance, both ANGPTL3 LOF heterozygotes and noncarriers 
displayed >80% increase in cholesterol in large VLDL at 4 
hours after the meal when compared with ANGPTL3 LOF 
homozygotes (PiAUC=0.02 for ANGPTL3 LOF homozygotes 
versus noncarriers). In contrast, the high-fat meal did not give 
rise to an increase in cholesterol levels of small VLDL, IDL, 
and LDL particles for any of the groups; rather, there was 
a small decrease in cholesterol within these smaller apoB-
carrying lipoprotein particles.
The postprandial response to the oral fat challenge in 
total fatty acids, β-hydroxybutyrate, and lactate is shown in 
Figure 4. Homozygous ANGPTL3 LOF carriers had markedly 
lower total fatty acids at all timepoints in comparison with 
the other 2 groups and showed essentially no postprandial in-
crease in fatty acid concentrations. Although the absolute con-
centration of omega-3 fatty acids was essentially unaffected 
by the fat challenge, the proportion of omega-3 fatty acids to 
total fatty acids increased after the meal in ANGPTL3 LOF 
homozygotes compared with other groups (PiAUC=0.0003; 
Figure VI in the online-only Data Supplement). The responses 
in absolute levels of saturated and monounsaturated fatty 
acids followed similar patterns as that of total fatty acids, 
with essentially no postprandial response for ANGPTL3 LOF 
homozygotes; however, the relative proportion of monounsat-
urated fatty acids increased for all groups (Figure VI in the 
online-only Data Supplement). The shape of the postprandial 
response in ketone bodies was broadly similar for ANGPTL3 
LOF carriers and noncarriers, but the concentrations of 
β-hydroxybutyrate were maintained elevated in the homo-
zygous ANGPTL3 LOF carriers (Figure 4). ANGPTL3 LOF 
carriers also displayed consistently higher lactate levels after 
the fat meal challenge and increases in postprandial citrate 
and acetate levels. Among other nonlipid biomarkers, GlycA 
(a marker of chronic inflammation) levels showed a blunted 
postprandial response in ANGPTL3 LOF homozygotes, pos-
sibly indicating a smaller inflammatory effect of the high-fat 
meal (PiAUC=0.03; Figure 4). Postprandial responses for other 
selected biomarkers are shown in Figure VII in the online-
only Data Supplement.
Discussion
In the present work, we describe a detailed metabolic signature 
associated with ANGPTL3 deficiency in humans. Because 
ANGPTL3 deficiency is known to influence postprandial lipid 
metabolism via modulation of lipoprotein lipase activity,21 we 
considered it particularly interesting to investigate the fine-
grained metabolic effects of ANGPTL3 LOF also after a high-
fat meal. We found that ANGPTL3 deficiency is characterized 
by markedly low levels of fasting and postprandial LDL and 
Figure 3. Effects of ANGPTL3 (angiopoietin-like protein 3) loss-of-function (LOF) variant on fatty acids and polar metabolites. Effect estimates are shown as 
difference in SD-scaled concentration units per ANGPTL3 S17X allele (additive model). Error bars indicate 95% CIs. Filled and open circles denote false dis-
covery rate–corrected P value for association below and above 0.05, respectively.
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Figure 4. Effects of ANGPTL3 (angiopoietin-like protein 3) loss-of-function (LOF) carrier status on metabolic response to an oral fat tolerance test. Results are 
shown as mean concentration and SEs at fasting and postprandial blood sample draw for selected biomarkers. Left axes indicate concentrations in absolute 
units, and right axes indicate concentrations in SD-scaled units. PiAUC indicates significance of difference in incremental area under the curve, reflecting meal 
response for ANGPTL3 S17X LOF homozygotes vs noncarriers. IDL indicates intermediate-density lipoprotein; LDL, low-density lipoprotein; and VLDL, very-
low-density lipoprotein.
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VLDL cholesterol, as well as other measures of TRL. In par-
ticular, individuals with 2 inactivating mutations in ANGPTL3 
and no measurable concentration of ANGPTL3 protein 
showed essentially no increase in TRL in response to a high-
fat meal. The low lipid levels among these homozygote car-
riers, who effectively act as human knockouts for ANGPTL3, 
were maintained after the oral fat challenge without evidence 
for adverse compensatory effects on the extensive metabolic 
biomarker panel examined in this study.
The main findings of our study are 4-fold: first, we found 
that ANGPTL3 deficiency results in similar reductions in 
magnitude for LDL and VLDL cholesterol, when scaled to 
the same variation in each lipid measure. Thus, ANGPTL3 
inhibitors should be more effective in lowering VLDL cho-
lesterol as compared with statins or PCSK9 inhibitors,19,20 
suggesting added benefit of ANGPTL3 inactivating therapy 
in individuals with combined dyslipidemias. This finding has 
clinical relevance, because increasing evidence suggests that 
the cholesterol content of VLDL and other TRLs is causally 
implicated in the development of CVD, independent of LDL 
cholesterol.2,3,27 Although TRLs have been suggested to play a 
causal role in CVD in Mendelian randomization studies,28 the 
triglycerides per se are unlikely to be the causal factor because 
these lipids are not accumulating in the atherosclerotic plaque. 
In contrast, the cholesterol within TRLs and their remnants 
can accumulate in the arterial intima and even get trapped 
more easily than LDL cholesterol.2 In line with our results, 
a recent phase 1 trial on antisense oligonucleotides targeting 
hepatic ANGPTL3 mRNA has reported ≤60% reduction in 
VLDL cholesterol and 33% reduction in LDL cholesterol.18
Second, the detailed profiling of lipoprotein subclasses re-
vealed that the absolute concentrations of both cholesterol and 
triglycerides in most lipoprotein subclasses were reduced in 
ANGPTL3 LOF carries compared with noncarriers. However, 
the proportion of cholesterol (relative to the total lipid con-
centration in a given subclass) was reduced and the proportion 
of triglycerides increased in small and medium-sized VLDL 
and IDL subclasses. These results indicate that ANGPTL3 
deficiency leads to less cholesterol load in the composition 
of TRL, which could potentially contribute to explain the 
lower CVD risk observed among ANGPTL3 LOF carriers. 
We observed no clear differences in the patterns of postpran-
dial response of TRL measures for ANGPTL3 LOF heterozy-
gotes as compared with noncarriers. In contrast, there was a 
remarkable lack of increase in TRL after the fatty meal intake 
among the 6 individuals with complete ANGPTL3 deficiency, 
as observed previously with narrower panel of lipid meas-
ures.21,29 This lack of a dose-dependent postprandial response 
could suggest that therapeutic inhibition of ANGPTL3 may 
only alleviate the increase in TRL after a meal intake if protein 
levels of ANGPTL3 are lowered to a high extent. To this re-
gard, we have recently determined that plasma ANGPTL3 <60 
ng/mL represents a threshold associated with marked reduc-
tions in fasting lipid and lipoprotein concentrations30; given 
the baseline plasma ANGPTL3 concentration among controls 
in the present study (Table), the lowering effects reported for 
ANGPTL3-LRx, ≥20 mg dose, should be sufficient to achieve 
ANGPTL3 levels below this threshold.18 Further studies are 
required to elucidate whether this extent of plasma ANGPTL3 
reduction is sufficient to substantially blunt the postprandial 
response in TRL or whether complete ANGPTL3 deficiency 
is required to observe this.
Third, we found that ANGPTL3 deficiency causes an eleva-
tion of fasting concentrations of the ketone β-hydroxybutyrate, 
which was maintained throughout the postprandial response. 
During ketogenesis in the liver, fatty acids are converted 
into ketone bodies via β-oxidation to produce energy. As 
ketogenesis is elevated when the influx of fatty acids into 
the liver is increased,31 the present observation may indicate 
that complete ANGPTL3 deficiency is accompanied by an 
increased hepatic utilization of fatty acids derived from the 
lipolysis of TRL or from adipose tissue. However, because 
the shape of postprandial response in β-hydroxybutyrate and 
the other ketone body measured, acetoacetate, was similar 
independent of the ANGPTL3 carrier status, one could spec-
ulate that this phenomenon might be related to partitioning 
of adipose tissue–derived fatty acid during the interprandial 
phase. However, this issue requires further investigations. 
Similarly to β-hydroxybutyrate, lactate levels were consist-
ently higher at fasting and after the meal challenge for com-
plete ANGPTL3 deficiency. This may indicate an enhanced 
conversion of pyruvate to lactate instead of its routing to the 
acetate pathway, consistent with the reduced concentration of 
acetate in the LOF carriers. These observations may suggest 
that ANGPTL3 deficiency is causing a modest shift of energy 
substrate utilization. The potential health effects of enhanced 
ketone body production remain unclear, but large epidemi-
ological studies have generally reported only weak or null 
associations of ketone bodies with cardiometabolic risk fac-
tors and disease outcomes.22
A further insight from this study arises from the meta-
bolic biomarkers not associated with ANGPTL3 deficiency, 
in particular for the homozygous carriers. These null results 
suggest there are no substantial adverse effects of complete 
absence of ANGPTL3 protein on amino acids and glycolysis-
related metabolites, neither at fasting nor as a compensatory 
mechanism for the absence of postprandial lipid increase. 
This is informative for the safety of ANGPTL3-inhibiting 
therapeutics, because many of these metabolites have been 
shown to be biomarkers of the risk for type 2 diabetes mel-
litus and CVD events.23,26 This is also the case for several of 
the relative proportions of fatty acid analyzed in this study. 
The observed modulations in the fatty acid balance for the rel-
ative proportions of saturated and omega-3 fatty acids could 
potentially be unfavorable in terms of cardiovascular risk, but 
the causal relations of these measures remain unclear. For the 
postprandial effects, it is noteworthy that the inflammatory bi-
omarker GlycA was low in ANGPTL3 LOF homozygotes and 
less elevated in the postprandial stage; such blunted increase 
in low-grade inflammation in response to a fatty meal might 
contribute to additional risk-reducing effects beyond lipids. 
Overall, these results illustrate the potential of wider metabolic 
profiling of human knockouts for drug targets for elucidating 
molecular mechanisms and potential metabolic side effects.
The strengths of the present study include a unique 
setting with fasting and postprandial measurements in 
ANGPTL3 LOF carriers, including the rare instance of 6 
individuals with complete ANGPTL3 deficiency. We used 
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NMR metabolomics to obtain detailed measures of lipid me-
tabolism and nonlipid biomarkers from multiple metabolic 
pathways. There are also potential limitations in our study. 
First, we acknowledge that other metabolomics assays ca-
pable of capturing additional blood metabolites could further 
contribute to characterize the metabolic effects beyond lipid 
metabolism. Second, despite the large effects on many lipid 
levels caused by ANGPTL3 deficiency, the small sample size 
provided limited power to detect all relevant metabolic asso-
ciations, in particular for robustly comparing differences in 
the postprandial response. Third, the biophysical properties 
of triglyceride-rich chylomicrons and the largest VLDL par-
ticles that are elevated in the postprandial state may impair 
the accuracy of the NMR-based quantification of lipids in 
these particles. This can lead to an underestimation of the 
postprandial lipid concentration in these large lipoprotein 
particles, as observed previously.24 In the present study, this 
may cause a slight underestimation of the postload differ-
ences of VLDL lipids between individuals with complete 
ANGPTL3 deficiency compared with heterozygotes and 
noncarriers. As illustrated in Figure I in the online-only Data 
Supplement, the spectral signals originating from lipoprotein 
lipids are almost exclusively confined to 2 large peaks, and 
the effects of chylomicrons do generally not affect the quan-
tification of other metabolites in different spectral areas or 
to the accuracy of smaller lipoprotein particles. Finally, our 
study was limited to characterize carriers of ANGPTL3 S17X 
LOF mutation only. Thus, there is a need for further meta-
bolic characterization of other LOF variants in the ANGPTL3 
gene. Detailed metabolic profiling in large biobanks with 
sequencing information available provides an opportunity 
to enable this and further extend applications to other lipid-
lowering targets.20,32
In conclusion, this detailed metabolic profiling study 
demonstrates that ANGPTL3 deficiency is characterized by 
substantial reductions in VLDL particles and their remnants 
and a lower cholesterol content in these lipoproteins. Further, 
complete ANGPTL3 deficiency leads to virtual absence of 
postprandial increase in TRL. These findings support the 
increasing body of evidence indicating that genetic inhibition 
of ANGPTL3 causes a broad range of beneficial lipid changes, 
without adverse compensatory metabolic effects. Detailed 
metabolic profiling in trials of pharmacological inactivation of 
ANGPTL3 could further help to confirm these findings in clin-
ical settings and, in combination with the genetic evidence, 
uncover potential off-target effects.33
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Highlights
• ANGPTL3 (angiopoietin-like protein 3) deficiency results in similar reductions in LDL (low-density lipoprotein) cholesterol and many triglycer-
ide-rich lipoprotein lipids measures, such as VLDL (very-low-density lipoprotein) cholesterol, with no evidence of substantial adverse effects 
on the comprehensive panel of circulating metabolite biomarkers tested here.
• In particular, ANGPTL3 deficiency results in reduction of cholesterol content in triglyceride-rich lipoproteins and their remnants, which have 
been highlighted as risk factor for cardiovascular disease independently of LDL levels.
• Homozygous ANGPTL3 loss-of-function carriers show essentially no postprandial increase in triglyceride-rich lipoproteins and fatty acids in 
response to a fat challenge and display consistently elevated postprandial levels of ketone body β-hydroxybutyrate when compared with non-
carriers, suggesting enhanced hepatic fatty acid β-oxidation.
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